Takayasu ArteritisNCT07149805
Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta
An observational study of Takayasu Arteritis, run by Peking Union Medical College Hospital.
Trial summary
The long-term prognosis and optimal management for Takayasu arteritis(TA) patients with severe stenosis of the descending thoracic and abdominal aorta remain undefined. We want to compare the clinical outcomes of surgical intervention and medical management. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Takayasu Arteritis
- What is being tested?
- open surgery or interventional treatment
- Type of treatment
- Surgery or procedure
- How many people
- 78 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2004to 1 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: inpatients at Peking Union Medical College Hospital
Who may be able to join
- fulfilling the 1990 American College of Rheumatology criteria for the diagnosis of TA;
- having at least one site with severe narrowing in the descending thoracic and abdominal aorta;
- having symptoms caused by TA-related stenosis, such as uncontrolled hypertension, heart failure, renal ischemia, dizziness, visual disturbances, and claudication
Who cannot join
- Patients with arterial stenosis due to other reasons (such as typical atherosclerosis, congenital coarctation of the aorta, and anatomical abnormality) were excluded
About this study
Official title: Surgery Improves Survival Rate in Patients With Takayasu Arteritis: a Retrospective Observational Study
The long-term prognosis and optimal management for Takayasu arteritis(TA) patients with severe stenosis of the descending thoracic and abdominal aorta remain undefined. We want to compare the clinical outcomes of surgical intervention and medical management.
- Conditions
- Takayasu Arteritis
- Being tested
- open surgery or interventional treatment
- Medical subject headings
- Takayasu Arteritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
open surgery or interventional treatmentProcedure or surgery
open surgery or interventional treatment
| Study group | Role | What they receive |
|---|---|---|
| surgerical group | Patients who underwent surgical treatment Receives: Procedure: open surgery or interventional treatment | |
| conservative group | Patients who underwent conservative treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
all-cause mortality rate
Measured: Patients underwent follow-up from discharge until study termination (3 years to 11 years) or death, whichever came first
all-cause mortality rate
Measured: Patients underwent follow-up from discharge (3 years to 11 years) until study termination or death, whichever came first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2025
- Study start1 Jan 2004
- Primary completion1 Jan 2025
- Study completion1 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Takayasu ArteritisStudies of the same condition, open and under way.
- More trials run by Peking Union Medical College HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 78 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yuexin Chen, Peking Union Medical College Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07149805
- Sponsor's protocol ID
- 2022-PUMCH-A-191
- Other IDs
- BJZQ2024001, UBJ06532
- Status last verified
- Jul 2025
- First submitted
- 18 Jul 2025
- Last updated
- 2 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: all collected IPD
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surgery Improves Survival Rate in Patients With Takayasu Arteritis: a Retrospective Observational Study
- ClinicalTrials.gov ID
- NCT07149805
- Acronym / sponsor ID
- 2022-PUMCH-A-191
- Conditions
- Takayasu Arteritis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 78 participants (actual)
- Lead sponsor
- Peking Union Medical College HospitalUniversity, hospital or other
- Study start
- 1 Jan 2004 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 1 Jan 2025 (actual)
- First posted
- 2 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The long-term prognosis and optimal management for Takayasu arteritis(TA) patients with severe stenosis of the descending thoracic and abdominal aorta remain undefined. We want to compare the clinical outcomes of surgical intervention and medical management.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| surgerical group | – | Procedure: open surgery or interventional treatmentPatients who underwent surgical treatment |
| conservative group | – | –Patients who underwent conservative treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- inpatients at Peking Union Medical College Hospital
Key inclusion criteria (3 listed)
- fulfilling the 1990 American College of Rheumatology criteria for the diagnosis of TA;
- having at least one site with severe narrowing in the descending thoracic and abdominal aorta;
- having symptoms caused by TA-related stenosis, such as uncontrolled hypertension, heart failure, renal ischemia, dizziness, visual disturbances, and claudication
Key exclusion criteria (1 listed)
- Patients with arterial stenosis due to other reasons (such as typical atherosclerosis, congenital coarctation of the aorta, and anatomical abnormality) were excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| open surgery or interventional treatmentopen surgery or interventional treatment | Procedure or surgery | surgerical group |
Primary outcome
all-cause mortality rate
Time frame: Patients underwent follow-up from discharge until study termination (3 years to 11 years) or death, whichever came first
all-cause mortality rate
Time frame: Patients underwent follow-up from discharge (3 years to 11 years) until study termination or death, whichever came first
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2025.
- Individual participant dataSharing planned: Yes. all collected IPD
Related trials for Takayasu Arteritis
RecruitingObservational study
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Takayasu's Arteritis, Giant Cell Arteritis
Not yet recruiting
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large Vessel Vasculitis, Takayasu Arteritis
RecruitingObservational study
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Not yet recruitingObservational study
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
RecruitingPhase 4
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Takayasu Arteritis, run by Peking Union Medical College Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
all-cause mortality rate (time frame: Patients underwent follow-up from discharge until study termination (3 years to 11 years) or death, whichever came first). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2025.